Malecare Prostate Cancer Support Group

Drugs & Treatments

On The Horizon – MDV3100 in Men With Advanced Prostate Cancer Study Will Be Stopped Early and MDV3100 Offered to All Participants

It was announced yesterday that the Independent Data Monitoring Committee (IDMC) has informed the the pharmaceuticals, Medivation and Astellas of positive results from a planned interim analysis of the Phase 3 AFFIRM trial of MDV3100 in men with advanced prostate cancer previously treated with chemotherapy. The monitoring committee found that MDV3100, the first androgen receptor [...]

By |2017-10-19T10:51:56-04:00November 4th, 2011|Advanced Prostate Cancer, Chemo Therapy Failure, Clinical Trials, Clinical Trials, Drugs & Treatments, MDV3100, On The Horizon, Uncategorized|1 Comment
Read More

Androgen Receptor Genes Have An Opposite Effect In Prostate & Breast Cancers

A study at The Cleveland Clinic has discovered that a gene – known as an androgen receptor (AR) is present in both breast and prostate cancers, but the gene has opposite effects on these diseases. The AR gene promotes prostate cancer when the gene is “turned on,” but in breast cancer the AR gene promotes [...]

By |2017-10-19T10:51:56-04:00November 2nd, 2011|Advanced Prostate Cancer, Drugs & Treatments, General Information, genetics, Research, Uncategorized, Understanding APC|0 Comments
Read More

The Role of BRCA2 Mutations in Aggressive Prostate Cancer

According to research published today in the British Journal of Cancer, routine testing for a faulty BRCA2 gene (Kote-Jarai Z et al, BRCA2 is a gene contributing to young onset prostate cancer: implications for genetic testing in prostate cancer patients British Journal of Cancer (2011) doi:10.1038/bjc.2011.383) in men under 65 years with prostate cancer could [...]

By |2011-11-01T11:53:48-04:00November 1st, 2011|Advanced Prostate Cancer, BRCA2, Drugs & Treatments, General Information, genetics, PARP inhibitors, Research, Uncategorized, Understanding APC|1 Comment
Read More

Alpha Blockers Linked to Prostate Cancer Relapse

A retrospective study has just been published that shows that the risk of experiencing a biochemical recurrence (PSA recurrence) after radical prostatectomy to treat prostate cancer increased significantly in men who received alpha blockers for lower urinary tract symptoms (LUTS) after surgery. When compared to men who did not receive alpha blockers, those who did [...]

By |2017-10-19T10:51:57-04:00October 26th, 2011|Advanced Prostate Cancer, Drugs & Treatments, General Information, Uncategorized, Understanding APC|0 Comments
Read More
Go to Top